Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate.

Barth BM, Shanmugavelandy SS, Kaiser JM, McGovern C, Altınoğlu Eİ, Haakenson JK, Hengst JA, Gilius EL, Knupp SA, Fox TE, Smith JP, Ritty TM, Adair JH, Kester M.

ACS Nano. 2013 Mar 26;7(3):2132-44. doi: 10.1021/nn304862b. Epub 2013 Feb 14.

2.

Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia.

Barth BM, I Altinoğlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP Jr, Claxton DF, Kester M.

ACS Nano. 2011 Jul 26;5(7):5325-37. doi: 10.1021/nn2005766. Epub 2011 Jul 8.

PMID:
21675727
3.

FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.

Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, Mirzapoiazova T, Garcia JG, Natarajan V.

J Biol Chem. 2009 Feb 27;284(9):5467-77. doi: 10.1074/jbc.M805186200. Epub 2009 Jan 1.

4.

Photodynamic therapy using nanoparticle loaded with indocyanine green for experimental peritoneal dissemination of gastric cancer.

Tsujimoto H, Morimoto Y, Takahata R, Nomura S, Yoshida K, Horiguchi H, Hiraki S, Ono S, Miyazaki H, Saito D, Hara I, Ozeki E, Yamamoto J, Hase K.

Cancer Sci. 2014 Dec;105(12):1626-30. doi: 10.1111/cas.12553. Epub 2014 Nov 5.

5.

Sphingosine kinase and sphingosine 1-phosphate in asthma.

Lai WQ, Wong WS, Leung BP.

Biosci Rep. 2011 Apr;31(2):145-50. doi: 10.1042/BSR20100087. Review.

PMID:
21091442
6.

De novo biosynthesis of dihydrosphingosine-1-phosphate by sphingosine kinase 1 in mammalian cells.

Berdyshev EV, Gorshkova IA, Usatyuk P, Zhao Y, Saatian B, Hubbard W, Natarajan V.

Cell Signal. 2006 Oct;18(10):1779-92. Epub 2006 Mar 10.

PMID:
16529909
7.

Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.

Shemesh CS, Hardy CW, Yu DS, Fernandez B, Zhang H.

Photodiagnosis Photodyn Ther. 2014 Jun;11(2):193-203. doi: 10.1016/j.pdpdt.2014.02.001. Epub 2014 Mar 19.

PMID:
24657627
8.

FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.

Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O.

Cancer Res. 2010 Nov 1;70(21):8651-61. doi: 10.1158/0008-5472.CAN-10-1388. Epub 2010 Oct 19.

9.

Human cytomegalovirus regulates bioactive sphingolipids.

Machesky NJ, Zhang G, Raghavan B, Zimmerman P, Kelly SL, Merrill AH Jr, Waldman WJ, Van Brocklyn JR, Trgovcich J.

J Biol Chem. 2008 Sep 19;283(38):26148-60. doi: 10.1074/jbc.M710181200. Epub 2008 Jul 20.

10.

Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells.

Schnitzer SE, Weigert A, Zhou J, Brüne B.

Mol Cancer Res. 2009 Mar;7(3):393-401. doi: 10.1158/1541-7786.MCR-08-0156. Epub 2009 Feb 24.

11.

Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis.

Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S, Takabe K.

Cancer Res. 2012 Feb 1;72(3):726-35. doi: 10.1158/0008-5472.CAN-11-2167.

12.

Sphingosine kinase/sphingosine 1-phosphate signalling in central nervous system.

Okada T, Kajimoto T, Jahangeer S, Nakamura S.

Cell Signal. 2009 Jan;21(1):7-13. doi: 10.1016/j.cellsig.2008.07.011. Epub 2008 Jul 22. Review.

PMID:
18694820
13.

Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling.

Rani CS, Wang F, Fuior E, Berger A, Wu J, Sturgill TW, Beitner-Johnson D, LeRoith D, Varticovski L, Spiegel S.

J Biol Chem. 1997 Apr 18;272(16):10777-83.

14.

Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy.

Huwiler A, Zangemeister-Wittke U.

Crit Rev Oncol Hematol. 2007 Aug;63(2):150-9. Epub 2007 Jun 7. Review.

PMID:
17560117
15.

Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O.

Cancer Res. 2005 Dec 15;65(24):11667-75.

16.

Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R.

Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19.

17.

Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.

Bae SM, Kim YW, Kwak SY, Kim YW, Ro DY, Shin JC, Park CH, Han SJ, Oh CH, Kim CK, Ahn WS.

Cancer Sci. 2007 May;98(5):747-52.

18.

The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.

Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA.

FASEB J. 2003 Aug;17(11):1411-21.

PMID:
12890694
19.

Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.

Zhang B, Jia H, Liu J, Yang Z, Jiang T, Tang K, Li D, Huang C, Ma J, Shen GX, Ye D, Huang B.

J Immunol. 2010 Dec 15;185(12):7199-206. doi: 10.4049/jimmunol.1001876. Epub 2010 Nov 10.

20.

Supplemental Content

Support Center